Last updated: February 27, 2026
What is NDC 69292-0538?
NDC 69292-0538 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy developed by Novartis for spinal muscular atrophy (SMA) in pediatric patients under two years of age. Approved by the FDA in May 2019, Zolgensma is a one-time infusion designed to address the genetic root cause of SMA, a rare neuromuscular disorder.
Market Size and Demographics
| Metric |
Data |
Source |
| Incidence of SMA in the U.S. |
1 in 11,000 live births |
[1] |
| Approximate diagnosed patients under age 2 (U.S.) |
350–500 |
[2] |
| Global SMA patient population (all ages) |
50,000–75,000 |
[3] |
| U.S. pediatric SMA patients eligible for gene therapy |
300–400 |
[2] |
The market focuses on infants diagnosed with SMA type 1 or 2, with the potential for expansion into older pediatric patients as guidelines evolve.
Competitive Landscape
| Therapy |
Mode of Action |
Approval Year |
Price (USD) |
Notes |
| Zolgensma (NDC 69292-0538) |
Gene therapy via AAV9 |
2019 |
$2.125 million |
One-time infusion |
| Spinraza (nusinersen) |
Antisense RNA modulation |
2016 |
$750,000 first year, $375,000 annually thereafter |
Multidose injections |
| Evrysdi (risdiplam) |
Oral SMN2 splicing modifier |
2020 |
$340,000 annually |
Oral administration |
Zolgensma's high upfront cost positions it as a premium therapy, with market competition from Spinraza and Evrysdi characterized by ongoing treatment costs.
Price Projection Assumptions
Current Pricing and Reimbursement Trends
- Initial Price: $2.125 million per dose (FDA-approved in 2019)
- Market Penetration: Rapid uptake in major markets, especially in the U.S.
- Reimbursement: Negotiated through payers, with Novartis offering outcomes-based agreements.
- Pricing Pressures: Cost containment policies and increased use of alternative therapies.
Factors Influencing Future Prices
- Generics or biosimilars: Unlikely within direct competition, but manufacturing efficiencies could reduce costs.
- Market expansion: Approvals for older SMA populations could increase total eligible patients, leveraging economies of scale.
- Regulatory changes: New policies on high-cost therapies could impose price caps or value-based pricing.
- Manufacturing costs: May decline with technological advances, potentially lowering price margins.
Price Trajectory and Market Penetration
| Year |
Estimated Global Patients Treated |
Projected Market Share |
Potential Price Range (USD) |
Comments |
| 2023 |
2,000–3,000 |
20–30% of eligible patients |
$2 million–$2.2 million |
Full market access, stabilization |
| 2024 |
4,000–6,000 |
30–50% |
$1.9 million–$2.1 million |
Expanded insurance coverage |
| 2025 |
6,000–9,000 |
50–70% |
$1.8 million–$2 million |
Market maturity, policy pressure |
As overall diagnosis and treatment rates increase, unit prices could decline marginally due to competitive pressures and reimbursement negotiations.
Revenue Projections
| Year |
Estimated Revenue (USD Million) |
Calculation Basis |
| 2023 |
4,000–6,600 |
2,000 × $2 million–$2.2 million |
| 2024 |
7,600–12,600 |
4,000 × $1.9 million–$2.1 million |
| 2025 |
10,800–18,000 |
6,000 × $1.8 million–$2 million |
The revenue growth depends on the actual diagnosis rates, geographic expansion, insurer acceptance, and competitive dynamics.
Regulatory and Policy Risks
- Pricing Regulations: Governments may impose price caps, influencing the list price.
- Reimbursement Models: Shift toward outcomes-based payments may pressure margins.
- Approval for Broader Indications: Can expand patient base but may influence pricing strategies.
Key Takeaways
- NDC 69292-0538 (Zolgensma) remains a premium-priced gene therapy with limited competition.
- Market penetration is sizable but subject to reimbursement policies and diagnosis rates.
- Price projections suggest potential slight declines driven by market dynamics, but prices are likely to remain high through at least 2025.
- Revenue growth hinges on expanding indications, diagnosis, and cost-effective access.
FAQs
Q1: What determines the long-term pricing of Zolgensma?
A1: Market competition, manufacturer costs, reimbursement negotiations, and regulatory policies.
Q2: How could the SMA treatment landscape influence Zolgensma pricing?
A2: Introduction of effective oral therapies may pressure prices and reimbursement strategies.
Q3: Are there prospects for price reductions?
A3: Marginal reductions are possible as manufacturing efficiencies improve and market dynamics evolve.
Q4: How does the market size compare globally?
A4: Smaller than the U.S. market but growing, especially in Europe and Asia with increasing diagnosis.
Q5: What are risks to revenue growth?
A5: Policy reforms, generic competition, and changes in clinical guidelines.
References
[1] Finkel, R. S., et al. (2018). "Diagnosis, management, and emerging therapies for spinal muscular atrophy." Nature Reviews Neurology.
[2] US FDA. (2019). "Zolgensma (onasemnogene abeparvovec-xioi) Approval Announcement."
[3] Global Data. (2022). "Spinal Muscular Atrophy Market Analysis."
